Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis
Open Access
- 1 September 2025
- journal article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (6) , 1529-1539
Abstract
Background and Aims: Evidence comparing longitudinal liver stiffness measurements (LSMs) dynamics to on-treatment LSM for predicting clinical outcomes in patients receiving etiology therapy is limited. This study aimed to assess the prognostic value of on-treatment LSM in patients with chronic hepatitis B (CHB) receiving antiviral therapy. Approach and Results: This prospective cohort included patients with CHB and significant fibrosis or cirrhosis. Liver-related events (LREs) were defined as hepatic decompensation, liver transplantation, or liver-related death. The association between LREs and baseline, on-treatment, and dynamic changes in LSM was analyzed. A total of 1116 patients with CHB, including 875 (78.4%) diagnosed with cirrhosis, were followed for a median of 7.5 (2.5–9.5) years. On-treatment LSM was the most reliable predictor of 3-year and 5-year outcomes (AUROC: 0.72–0.78) after 1–3 years of antiviral therapy, outperforming baseline LSM (AUROC: 0.59–0.65) and LSM changes (AUROC: 0.42–0.65). Patients with LSM <10 kPa at 1, 2, or 3 years of antiviral therapy have a much lower risk of LREs, with a 5-year cumulative incidence of 2.2%, 2.6%, and 2.7%, respectively. This finding held true in the cirrhosis subgroup, in the validation cohort, and for predicting decompensations alone. Notably, patients with on-treatment LSM <10 kPa showed better restoration of lobular architecture assessed by liver biopsies. Conclusions: On-treatment LSM measured 1–3 years after antiviral therapy offers superior predictive accuracy for LREs compared with baseline or LSM changes, with LSM <10 kPa indicating a significantly lower risk, likely due to improved lobular architecture.Keywords
This publication has 22 references indexed in Scilit:
- Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis BClinical Gastroenterology and Hepatology, 2021
- Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavirJournal of Viral Hepatitis, 2019
- Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78‐week prospective studyJournal of Gastroenterology and Hepatology, 2018
- New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatmentHepatology, 2016
- Reversibility of hepatitis B virus cirrhosis after therapy: who and why?Liver International, 2014
- Glutamine synthetase expression in activated hepatocyte progenitor cells and loss of hepatocellular expression in congestion and cirrhosisLiver International, 2013
- Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosisGut, 2012
- Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertensionJournal of Hepatology, 2009
- Non-invasive evaluation of liver fibrosis using transient elastographyJournal of Hepatology, 2008
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004